D'AddarioG., FelipE.: Non-small-cell lung
cancer: ESMO Clinical Recommendations for diagnosis, treatment and
follow-up.Ann Oncol, 20(Suppl 4):
68–70, 2009.
2.
Shepherd FA, Rodrigues Pereira J,
Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S,
Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D,
Bezjak A, Clark G, Santabárbara P, Seymour L; National Cancer Institute of
Canada Clinical Trials Group:Erlotinib in previously treated non–small-cell lung
cancer.N Engl J Med, 353:
123–132, 2005.
3.
PenelN., BlayJ.Y., AdenisA.: Imatinib as a possible
cause of severe rhabdomyolysis.N Engl J Med, 358:
2746–2747, 2008.
AnderliniP., BuzaidA.C., LeghaS.S.: Acute rhabdomyolysis
after concurrent administration of interleukin-2, interferon-alfa, and
chemotherapy for metastatic melanoma.Cancer, 76:
678–679, 1995.
6.
KhanF.Y.: Rhabdomyolysis: a
review of the literature.Neth J Med, 67:
272–283, 2009.
7.
VeeraputhiranM., SundermeyerM.: Rhabdomyolysis
resulting from pharmacologic interaction between erlotinib and
simvastatin.Clin Lung Cancer, 9:
232–234, 2008.
